Tiziana Life Sciences (TLSA) Accounts Payables (2017 - 2025)
Tiziana Life Sciences (TLSA) posted quarterly Accounts Payables of $7.2 million for Q4 2025, down 0.79% year-over-year from $7.2 million in Q4 2024, and little changed quarter-over-quarter from $7.2 million in Q2 2025.
Tiziana Life Sciences (TLSA) Accounts Payables (2017 - 2025) Analysis & Trends
Tiziana Life Sciences' Accounts Payables history runs 9 years deep, the most recent figure standing at $7.2 million for Q4 2025.
- In Q4 2025, Accounts Payables fell 0.79% year-over-year to $7.2 million; the TTM figure through Dec 2025 stood at $7.2 million (down 0.79% YoY), while the FY2025 annual figure was $7.2 million, down 0.79% from the prior year.
- Accounts Payables for Q4 2025 stood at $7.2 million, roughly flat from $7.2 million in the prior quarter.
- The five-year high for Accounts Payables was $8.9 million in Q2 2024, with the low at $3.8 million in Q2 2023.
- The 5-year median for Accounts Payables is $6.6 million (2021), against an average of $6.4 million.
- The sharpest annual moves came in 2023 and 2024: Accounts Payables slipped 28.58% in 2023, then jumped 137.04% in 2024.
- Tiziana Life Sciences' Accounts Payables stood at $6.2 million in 2021, then retreated by 19.72% to $5.0 million in 2022, then gained by 28.72% to $6.4 million in 2023, then advanced by 13.2% to $7.2 million in 2024, then fell by 0.79% to $7.2 million in 2025.
- Business Quant data shows TLSA's Accounts Payables at $7.2 million in Q4 2025, $7.2 million in Q2 2025, and $7.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Tiziana Life Sciences | 133.66 Mn | 129.65 Mn | - | 10.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.17 Mn |
| Jun 30, 2025 | 7.18 Mn |
| Dec 31, 2024 | 7.23 Mn |
| Jun 30, 2024 | 8.92 Mn |
| Dec 31, 2023 | 6.39 Mn |
| Jun 30, 2023 | 3.76 Mn |
| Dec 31, 2022 | 4.96 Mn |
| Jun 30, 2022 | 5.27 Mn |
| Dec 31, 2021 | 6.18 Mn |
| Jun 30, 2021 | 6.85 Mn |
| Dec 31, 2020 | 7.72 Mn |
| Jun 30, 2020 | 6.51 Mn |
| Dec 31, 2019 | 7.17 Mn |
| Jun 30, 2019 | 6.19 Mn |
| Dec 31, 2018 | 6.01 Mn |
| Jun 30, 2018 | 5.63 Mn |
| Dec 31, 2017 | 4.67 Mn |